Contribute Try STAT+ Today

For many people, the New Year is a time for new beginnings. But for many telehealth patients, the start of 2021 means being plunged back into 2019 as Congress prepares to walk back some of the pandemic-related coverage and payment flexibilities it instituted for 33 million seniors and people with disabilities.

In December 2020, I joined telehealth CEOs and health system leaders at the Department of Health and Human Services Telehealth Innovation Summit to make critical asks of the federal government after 2020’s monumental year for virtual care, in which Congress and HHS allowed new reimbursements for telemedicine visits broadly defined.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • Well said Hill. I agree 100%. Virtual visits can improve care, compliance and customer service. Proud to be working with HeraMed for pregnancy care virtually and we are blown away with the results. Keep up the great work!

Comments are closed.